Barclays (LON:BARC) analyst Steven Valiquette maintained a Buy rating on Universal Health (NYSE:UHS) on Friday, setting a price target of $160, which is approximately 20.77% above the present share price of $132.48.
Valiquette expects Universal Health to post earnings per share (EPS) of $2.84 for the first quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Universal Health, with an average price target of $148.11.
The analysts price targets range from a high of $160 to a low of $139.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $2.91 billion and a net profit of $349.67 million. The company's market cap is $11.26 billion.
According to TipRanks.com, Barclays analyst Steven Valiquette is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.1% and a 56.82% success rate.
Universal Health Services , Inc. operates as a healthcare management company, which through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. It operates through the following segments: Acute Care Hospital Services, Behavioral Health Care Services, and Other. The Other segment consists of centralized services such as information technology, purchasing, reimbursement, accounting and finance, taxation, legal, advertising, and design and construction. The company was founded by Alan B. Miller in 1979 and is headquartered in King of Prussia, PA.